drugset / Trial / NCT01433393

Double-blind Comparative Study of TAK-875

NCT01433393

Phase 3 Completed 192 enrolled Takeda
Parallel-group

Summary

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Timeline

Start
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasiglifam Small molecule 25 mg
Subject Fasiglifam Small molecule 50 mg

Indications